Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. Bone Marrow Transplant 2012 Jan;47(1):146-8
Date
03/02/2011Pubmed ID
21358681DOI
10.1038/bmt.2011.18Scopus ID
2-s2.0-84855736330 (requires institutional sign-in at Scopus site) 5 CitationsAuthor List
Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani MAuthor
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Antineoplastic Agents
Boronic Acids
Bortezomib
Female
Follow-Up Studies
Humans
Immunosuppressive Agents
Male
Middle Aged
Multiple Myeloma
Peripheral Blood Stem Cell Transplantation
Pyrazines
Retrospective Studies
Thalidomide
Transplantation, Autologous